A fast and reliable method for the determination of hemoglobinopathies and thalassemias by high-resolution accurate mass spectrometry (HRAM/MS) is presented. The established method was verified in a prospective clinical study (HRAM/MS vs. high-pressure liquid chromatography [HPLC]) of 5335 de-identified newborn samples from the Hamburg area. The analytical method is based on a dual strategy using intact protein ratios for thalassemias and tryptic digest fragments for the diagnosis of hemoglobinopathies. Due to the minimal sample preparation and the use of flow injection, the assay can be considered as a high-throughput screening approach for newborn screening programs (2 min/sample). Using a simple dried blood spot (DBS) extraction (tryptic digest buffer), the following results were obtained: (1) a carrier incidence of 1:100 newborns (35 FAS, nine FAC, eight FAD and two FAE), and (2) no homozygous affected patient was detected. Using the HRAM/MS protocol, an unknown Hb mutation was identified and confirmed by genetic testing. In addition to greater specificity toward rare mutations and β-thalassemia, the low price/sample (1-2€) as well as an automated data processing represent the major benefits of the described HRAM/MS method.
Introduction
Hemoglobinopathies and thalassemia are a group of autosomal recessive genetic diseases with global public health relevance [1] . There is a high incidence for hemoglobinopathies and thalassemias in the Mediterranean area, Middle East, Africa and Asia because of a selective advantage of heterozygous individuals against Plasmodium falciparum infection [2, 3] . These rare diseases mainly contain a mutation in one or both Hb-β chains or a misbalanced ratio between the α/β chains [4] . Besides the identification of Hb S in the homozygous form, combinations with Hb variants (e.g. Hb C, D and E) or β-thalassemia are the clinically most relevant types [5, 6] . The increasing carrier frequencies worldwide, especially in urban areas (e.g. Hamburg, one birth in 2385 newborns), underline the importance and the demand of a reliable diagnostic tool for hemoglobin-related disorders [7] . The newborn screening prevents early organ damage which otherwise would occur due to lack of preventive therapy [8] . Additionally, an early diagnosis will result in reduced hospitalizations and an efficient therapy management [9] . Early detection of both hemoglobinopathies and thalassemia requires a robust high-throughput method [10] . Therefore, we have assessed the possibility of HRAM/MS for this purpose and compared newborn screening results to the conventional high-pressure liquid chromatography (HPLC) method used frequently nowadays. of life. Blood taken by heel stick was spotted on filter paper (e.g. 903, Whatman), dried and sent by courier to the screening center. Blood spot samples were stored at 4 °C until analysis.
HPLC (Variant II) method
HPLC analyses were performed, within 5 days after bloodspots have been taken, on a VARIANT™nbs newborn screening system (Bio-Rad Laboratories, Munich, Germany) according to the manufacturer's recommendations. DBSs were eluted for 2 h by shaking with demineralized water and subsequently injected into the HPLC system (UV/VIS). All chromatograms were automatically analyzed and visually inspected for absent hemoglobin A and variant hemoglobins. Chromatograms below the threshold area of 500,000 were re-run with longer elution times and/or two punches per well. Simultaneously, identical plates were punched, sealed and shipped to Vienna (ARCHIMEDlife Science GmbH) for HRAM/MS analysis.
HRAM/MS method
DBS cards were punched as 3.2-mm spots into a well plate and each spot was extracted with 100 μL of tryptic digest buffer (40 mM NH 4 HCO 3 , 9% MeCN, 1 mM CaCl 2 , 5 mg/mL TPCK-treated trypsin from bovine pancreas) for 30 min at 37 °C and approximately 1000 rpm (Heidolph Unimax 1010). DBS cards prepared with pooled human blood were used as controls. Fifteen microliters of the supernatant and 85 μL of the quenching solution (40 mM NH 4 HCO 3 , 9% MeCN, 2% formic acid) were mixed for 1 min in a new well plate, covered with aluminum foil and 5 μL of the solution was directly injected into the mass spectrometer. Data acquisition was utilized by alternating two different full scan ranges (m/z 325-1000 for tryptic fragments and the second between 1045 and 1100). Especially, the narrow scan range (m/z 1045-1100) for the intact protein chains led to a significant improvement of signal to noise (S/N), which was beneficial for the detection of thalassemias.
Chromatography was performed on a Thermo Fisher Scientific Dionex Ultimate 3000RS. Samples (5 μL) were applied by flow injection (FIA) at room temperature. Mobile phase contained 18% MeCN with 0.1% formic acid in water. A flow gradient was used with the following conditions: 0 min, 0.04 mL/min; 0.42 min, 0.10 mL/min; 0.83 min, 0.2 mL/min; 1.67 min, 0.04 mL/min; with a total run time of 2 min. The autosampler temperature was set to 5 °C. Mass spectrometric detection was performed using a Thermo Scientific™ Q Exactive™ Focus Hybrid Quadrupole-Orbitrap operated in the positive ion electrospray ionization (HESI) mode. The source parameters of the mass spectrometer were optimized and maintained as shown in Figure S1 (see Supplementary Information). Nitrogen was used as sheath, auxiliary and sweep gas. Data were processed using Trace-Finder™ (Thermo Fisher) and an automatic data processing file was established. To exclude extraction or instrumentation issues, two run controls (human Hb, 150 mg/mL) were performed before and after each batch (maximum 92 samples) of newborns.
Genetic confirmation testing
Within the prospective study, two anonymized samples with divergent results (HPLC ≠ high-resolution mass spectrometry [HRMS]) were obtained. These samples were Sanger-sequenced at the University Medical Center Hamburg-Eppendorf, Institute of Pediatric Hematology and Oncology.
Results and discussion
Within the last few years, MS/MS-based assays were developed to overcome the limitations of well-established methods for the analysis of hemoglobinopathies, such as (1) HPLC: data processing and chromatographic separation or (2) isoelectric focusing (IEF): elaborate and timeconsuming sample preparation (not suitable for high throughput) [10, 11] . Additionally, MS/MS is widely used in newborn screening laboratories and enables definitive hemoglobin identification of a broad Hb variant portfolio [12, 13] . In general, two strategies were already presented, a top-down approach, which includes an enzymatic digest (e.g. trypsin) of the protein chains, and a bottomup approach, which is characterized by simple extraction of the protein and direct analysis of the whole protein [14] [15] [16] [17] [18] . The bottom-up strategy was investigated by Helmrich et al. on LC-TOF by using whole blood of adults and data interpretation was done by de-convoluted mass spectra [19] . Additionally, the identification of thalassemias was performed by calculations of the α/β ratio and led to conclusive results for β-thalassemias. Due to biological reasons, the hypothesis to identify α-thalassemias by using cut-off ratios (α/β) was not feasible [20] . With regard to published and experimentally derived values, a screening method for α-thalassemias would be of great interest but most probably an unambiguous assignment is currently restricted to genetic testing methods [21] .
Due to the increasing incidence of hemoglobin-related diseases worldwide, a high-throughput assay for hemoglobinopathies and thalassemias would be beneficial, especially with a focus on an early diagnosis and life-saving treatment [22] . Besides the transition of fetal (2α-/2γchains) to adult (2α-/2β-chains) hemoglobin within the first weeks after birth, the major challenge for a screening assay is the identification and differentiation between carrier-and sickle cell disease-positive samples [23, 24] . Due to a single mutation of clinical relevance in the βchain (e.g. Hb C, D, E), these Hb variants differ only by 1 Da for the entire protein. This fact leads to resolution issues by mass spectrometry for ion species with high m/z ratios (e.g.
[M + 15] 15+ ) [16] . To detect these mutations, a fine balanced ratio between S/N and resolution is crucial. For example, the [M + 15H] 15+ -charged β-chain of wildtype Hb gave a mass shift to Hb D of 0.06 Da. To address this resolution issue, different Orbitrap analyzers (Thermo Scientific™ Q Exactive™ Focus Hybrid [maximum resolution of 70k] vs.
Thermo Scientific™ Orbitrap Fusion™ Lumos™ Tribrid™ with a maximum resolution of 500k) were utilized. In general, the resolution correlates with the scan time, which leads to an increased cyclization time of the analytes in the detector cell at higher resolutions. With increased cyclization time, direct infusion experiments at 500k resolution end up in complete decomposition of the αand β-chains. By reducing the resolution from 500k (Lumos™) to 70k (Q Exactive™ Focus), we obtained the best balance concerning resolution and sensitivity. With a focus on general requirements of a clinical assay, which have to be highly robust, reliable and easy to handle (sample preparation to data processing), a dual-extraction strategy using a mixture of intact proteins and tryptic fragments was designed [25] . By this approach, the intact hemoglobin chains (α-/β-/γchains at [M + 15H] 15+ ) are primarily considered for the identification of β-thalassemias (minor or major form). In addition to the extraction of intact protein chains, the trypsin-containing (5 mg/mL) buffer is used for the generation of specific Hb fragments. This proteolytic digest of hemoglobin by using TPCK-treated trypsin from bovine pancreas leads to a distinctive identification of the clinically relevant Hb mutations (e.g. Hb C, D, E and S) under screening conditions (2 min/injection, no column-FIA). Within 30 min, a single extraction of a DBS (3.2-mm punch) provides a defined mixture of intact and tryptic fragments and the related supernatant was analyzed without further purification (e.g. filtration). The updated method is beneficial due to the easy and inexpensive sample preparation (1-2 €/sample) and thus suitable as a high-throughput assay (2 min/samples) for clinical screening purposes. In order to avoid any chromatographic separation and related bottlenecks (e.g. S/N, baseline stability), an LC method based on flow injection was developed (Figure 1) . The well-defined FIA peak was directly applied to an automatic data processing (TraceFinder™) and led to a conclusive output file by using a slightly adapted, literature known, calculation algorithm [22] . In contrast to MRM-or HPLCbased methods, additional information gained by the interpretation of intact protein chains showed beneficial performance toward the diagnosis of β-thalassemias. In 2017, a top-down approach was reported by Yu et al., which utilized a stable isotope-labeled internal standard (IS) for the calculation of α/β ratio [14] . In their presented work, an IS was mainly required to exclude unselective enzymatic cleavage of αor β-chain. By our developed HRAM/MS method, the correlation between αand βchains is determined on the protein level, which impairs standardization in the framework of a high-throughput approach. As the HRMS is performed on a qualitative level by simply comparing peak intensities of each individual, standardization is challenging and also not crucial for the identification of Hb disorders. To avoid any restriction for our strategy related to sample preparation or follow-up steps, a cut-off evaluation of random newborns as well as positive samples (known patients) was performed prior to the prospective study. During this method development period, a set of 27 patients with known Hb mutations from the metabolic laboratory in Hamburg were analyzed. Within this pool, different carrier-(e.g. FAS, FAC, β-thalassemia, etc.) as well as sickle cell disease-positive patients (e.g. FSS, co-inherited FSC, FAES) were determined by the HRAM/MS (see Table 1 ). In total, a similar overall performance of HRAM/ MS vs. HPLC was observed (see Table 1 , 1-7). Three patient samples (e.g. Hb Lepore, Hb Hamilton, co-inherited Hb Presbyterian/Ghanaian, Table 1 , 8-10), which were first determined by genetic testing, have also been confirmed by the described HRAM/MS method. By HPLC the following results were observed: (1) Hb Lepore = unknown peak identified ( 1, 10) . In the case of the Hb Presbyterian/ Ghanaian patient, full scan data by HRAM/MS provided all information, which enabled the identification of these (Figure 2A  and B) , was feasible.
Prospective screening study
After this proof-of-concept study, a prospective study with the metabolic laboratory in Hamburg was initiated.
In 2016, a pilot study with 17,000 newborns from the Hamburg area was performed by HPLC and confirmed by genetic testing. In brief, an Hb carrier incidence of 1:100 and a sickle cell disease frequency of 1:2500 were published [7] . A prospective study for performance evaluation (HRAM/MS vs. Biorad Variant II) of the established HRAM/MS was performed by investigating 5335 newborns on both analytical systems and resulted in the identification of 56 and 55 positive carriers, respectively (Table 2, 2-8) . Besides 54 matching results (35 FAS, nine FAC, eight FAD and two FAE) within these set of carriers, also some deviations between the methods were observed. As summarized in Table 2 , an additional FAES and an FAE carrier were identified by HPLC in contrast to the HRAM/MS (Table 2, 6-7 ). An increased Hb E signal by HPLC can be obtained due to bad sample quality or method constraints, which leads to low specificity toward β-thalassemia. Especially, a slight drop in chromatographic resolution causes unreliable quantification of the relevant peaks. Thalassemias are characterized by a misbalanced ratio between αand β-/γ-chains. In the case of a β-thalassemia minor, a calculated α/(β + γ) ratio of roughly 2 is expected. To increase assay sensitivity, a cut-off value of 1.75 was eventually selected for β-thalassemias (minor). For cut-off evaluation, around 1500 newborn samples as well as positive samples from the hematological outpatient clinic were investigated. Within this study, a clear distinction between healthy (α/ [β + γ] < 1.75) and β-thalassemia (α/[β + γ] > 1.75)-suspected newborns was possible ( Figure 3 ). Besides β-thalassemia, also a homozygous FSS or, for example, a co-inherited FSC can give an increased ratio. In 2016, a similar cut-off range at around 1.5 for α/β, which takes also into account the lower proton affinity of the β-chain, was presented for using whole blood of adults on a TOF analyzer [19] . For further improvement of the overall specificity toward β-thalassemias, a second-tier testing without a tryptic digest was performed by applying similar HRMS settings. Therefore, a single DBS was extracted for 30 min at room temperature with 100 μL of an aqueous 40 mM NH 4 HCO 3 (9% MeCN) to generate exclusively intact α, β and γ protein chains.
By applying the established cut-off and the secondtier protocol, it was possible to exclude two suspected β-thalassemia patients within the primary screening. In order to reduce background signals and increase S/N, only the [M + 14H] 14+ species (intact protein) of the α-chain and the [M + 15H] 15+ species of the βand γ-chains were compared and used for ratio calculations. A statistical data evaluation of gestational age to the intact Hb protein chain pattern (β and γ) showed no conclusive correlation within the study. It seems that after birth the ratio is highly variable and favors Hb-γ while transition to Hb-β is independent of gestational age and occurs in the weeks after birth [26] .
Within the primary HRAM/MS protocol (tryptic digest + intact protein), an FAE-suspected newborn by HPLC (Table 2, 6) was identified by HRAM/MS as a β-thalassemia with a ratio of α/(β + γ) = 3.4. By applying the second-tier testing algorithm, the described sample does not give any variation from the results of healthy newborns (α/[β + γ] < 1.75). The HRAM/MS resulted by the use of the established second-tier workflow in an Hb-β wildtype, which was confirmed by genetic testing.
Additionally, reprocessing of the mismatching FAES patient, according to HPLC (Table 2, 7) , underlines once more the major benefit of the HRAM/MS method. By simply reviewing the chromatogram and the mass spectra, an unknown signal (m/z 1088.5) was identified in the full scan mode (Figure 4, Table 2, 8) .
By Sanger sequencing, a mutation was identified, which is not included to the regularly applied primer panel. Related to these results, it can reasonably be concluded that the HRAM/MS method showed a greater specificity toward rare mutations in comparison to the HPLC (Table 2, 8) . In addition to the benefit of data reprocessing, the HRAM/MS output file can be adapted to implement additional Hb variants (e.g. for epidemiological or geographical reasons) [27] . Due to limitations in the chromatographic separation under high-throughput conditions, the HPLC method is restricted to some specific Hb mutations. This may lead to a misinterpretation of the screening results for thalassemias or rare Hb mutations (Table 1, 8-10) .
These results underline the power and the applicability of HRAM/MS in an untargeted screening protocol for rare mutations. Within the clinical study for newborn screening, deviations for two newborn samples were observed by HPLC vs. HRAM/MS (Table 2, 6-8) . Finally, the results of the HRAM/MS method were confirmed by genetic testing (UKE Hamburg, Pediatric Hematology and Oncology). During the regular NBS process, heterozygous Hb patterns, which were exclusively observed during the performed study, would not lead to a clinical ruling. Nevertheless, the HRAM/MS method is suited for the differentiation between hetero-and homozygous patients (see 
Conclusions
Our HRAM/MS method can be considered as an attractive alternative to the state-of-the-art methods (HPLC and IEF) for the detection of variations in hemoglobin chains. The HRAM/MS method is able to cope with the general requirements for a clinical screening assay such as (1) minimal sample preparation and handling, (2) high throughput (2 min/sample), (3) inexpensive (1-2 €/sample), (4) robust system (no maintenance -only one time source cleaning during the study) and (5) automated clinical assessment. From a technical point of view, the method is suitable for the identification of clinically relevant mutations and differentiation between hetero-and homozygous forms. The tested dual strategy, which investigates intact protein chains (α, β, γ) as well as tryptic peptides, represents a powerful tool for the diagnosis of hemoglobin-related diseases. Especially, the identification of β-thalassemias on intact protein levels depicts an advantage in comparison to HPLC. Due to the possibility of data reprocessing (full scan), an untargeted diagnostic protocol can be stated as an upcoming goal. In order to realize this aim, all known Hb mutations (approximately 1400) have to be implemented into a processing algorithm. Besides the described benefits, only the availability and the initial investment for an HRAM/MS analyzer have to be considered as drawbacks. Therefore, in the case of screening programs that are restricted to sickle cell disease, the conventional methods may suffice. For programs that encompass a larger array of hemoglobinopathies and thalassemias, the established high-throughput assay is a viable alternative and interesting approach to update regular newborn screening programs.
